Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

skin cancer vaccine

- PMLiVE

BriaCell advances personalised skin cancer immunotherapy vaccine candidate

Around 112,000 new cases of skin cancer will be diagnosed in the US in 2026

- PMLiVE

MSD and Moderna announce potential new vaccine for melanoma

The mRNA-based therapy, used with Keytruda, is designed specifically for each patient

- PMLiVE

Cases of skin cancer set to reach 263,000 in 2035 according to new report

The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe

- PMLiVE

NHS programme to give melanoma patients fast-track access to skin cancer vaccine

The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

- PMLiVE

British Skin Foundation receives £10,000 donation from Circle Health Group

The healthcare provider’s previous donation is supporting research into early melanoma detection

- PMLiVE

Merck shares positive ten-year results for Keytruda in advanced melanoma

More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year

- PMLiVE

BioNTech shares promising results for mRNA immunotherapy candidate in advanced melanoma

Melanoma is currently responsible for around 58,000 deaths globally every year

- PMLiVE

Moderna/Merck share positive three-year results for investigational skin cancer vaccine

More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024

- PMLiVE

FDA approves Iovance’s Amtagvi as first cellular therapy for advanced melanoma

Amtagvi is now the first one-time, individualised T cell therapy to be approved in the US for a solid tumour cancer

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma

Approximately 17,000 cases of melanoma are diagnosed in the UK every year

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by FDA for expanded melanoma use

More than 97,000 cases of melanoma are expected to be diagnosed in the US in 2023

- PMLiVE

Bristol Myers Squibb to acquire Mirati Therapeutics for up to $5.8bn

The transaction would mark a significant boost to the US drugmaker’s oncology portfolio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links